Interferon alpha in the treatment of Philadelphia-negative myeloproliferative neoplasms
Authors:
A. Hatalová; K. Slezáková; L. Masákova; M. Mistrík.; A. Bátorová
Authors‘ workplace:
Klinika hematológie a transfuziológie, LF UK , SZU Univerzitná nemocnica Bratislava
Published in:
Transfuze Hematol. dnes,23, 2017, No. 2, p. 73-81.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Introduction:
Interferon alfa (IFN-α) has been used for over 30 years to treat myeloproliferative neoplasms. Recombinant IFN-α (rIFN-α) and pegylated IFN-α (Peg-IFN-α) have been shown to provide effective therapy for essential thrombocythemia (ET) and polycythaemia vera (PV), as well as early stage primary myelofibrosis (PMF) in several clinical studies.
Patients and methods:
This report presents a retrospective analysis of 60 patients with MPN who were treated with rIFN-α or Peg-IFN-α outside clinical trials.
Results:
Retrospective stratification at diagnosis included 34 (57%) patients with PV, 5 (8%) with ET and 21 (35%) with PMF. Median age was 43 years (16-70). Median treatment duration was 107.5 months, with 11 patients treated with Peg IFN-α for a median duration of 24 months. Median follow up was 164 months. 24 patients (40%) achieved complete remission, 29 patients (48%) achieved partial remission and 7 patients (12%) failed to achieve partial remission. Toxicities were recorded in 42 patients (70%): chronic „flu-like syndrome“, psychiatric toxicity, hepatotoxicity, dermatotoxicity, ocular and neurotoxicity. Thirteen (22%) patients stopped the treatment because of toxicity.
Conclusion:
IFN-α effectively controls disease in a significant proportion of Ph-negative MPN patients. However, its use in clinical practice has unfortunately been limited by side effects. These results support the need for further efficacy studies of IFN-α in this group of patients.
Key words:
myeloproliferative neoplasms – polycythaemia vera – essential thrombocythemia – primary myelofibrosis – interferon alpha – pegylated interferon – effect of treatment – treatment toxicity
Sources
1. Isaacs A, Lindenmann J, Valentine RC. Virus interference. II. Some properties of interferon. Proc R Soc B 1957;147:268–273.
2. Nagata S, Taira H, Hall A, et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980;284(5754):316–320.
3. Stein BL,Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interferon Cytokine Res 2013;33:145–153.
4. Kiladjian JJ, Chomienne C, Fenaux P. Interferon–alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008;22:1990–1998.
5. Linkesch W, Gisslinger H, Ludwig H, et al. Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses. Acta Med Austriaca 1985;12:123–127.
6. Gisslinger H, Ludwig H, Linkesch W, Fritz E, Chott A, Radaskiewicz TH. Long-term interferon therapy for thrombocythosis in myeloproliferative diseases. Lancet 1989;2:634–637.
7. Silver RT. Interferon of treatment of myeloproliferative diseases. Semin Hematol 1990;27:6–14.
8. Šteruská M. Interferón alfa v liečbe hematologických malígnych ochorení. Vnitř Lek 1989;35:1164–1167.
9. Šteruská M, Hrubišková K, Bátorová A, et al. Thrombocytosis in myeloproliferative syndroma – effect of chemotherapy and interpheron alpha. Hematol Transfusiol 1994;2:15–21.
10. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 1998;83:1205–1213.
11. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013;6:49–58.
12. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular- response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006;108:2037–2040.
13. Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, clinical and biologic effects, and impact on quality of life.Cancer 2006;106:2397–2405.
14. Hasselbalch H. A new era for IFN-α in the treatment of Philadelphia--negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011;4:637–655.
15. Gissslinger H, Kralovics R, Gisslinger B, et al. AOP2014, a novel peg-proline interferon alpha 2b with improved pharmacokinetic properties is safe and well tolerated and shows promising efficacy in patients with polycytemia vera (PV). Blood 2012;120(21):175.
16. Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα 2b, induces high responses rates with low toxicity in patient with polycythemia vera. Blood 2015;126:1762–1769.
17. Passamonti F, Rumi E. Clinical relevance of JAK2 (V617F) mutant alele burden. Haematologica 2009;94:7–10.
18. Them NCC, Bagienski K, Berg T, et al. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol 2015;90:288–294.
19. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006;107:451–458.
20. Larsen TS, Møller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long –term treatment with alpha-interferon 2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009;14:331–334.
21. Jabbour E, Kantarijian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: Final results of a phase 2 study. Cancer 2007;110:2012–2018.
22. Ajzenberg N, Faile D, Lawrani L, et al. Pro-coagulant and pro-inflammatory effect of interferon alfa in myeloproliferative neoplasms. Blood 2016;128:1941.
23. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013;6:49–58.
24. Thiele J, Kvasnicka HM. The 2008 WHO Diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep 2009;4:33– 40.
25. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of European LeukemiaNet consensus conference. Blood 2009;113:4829–4833.
26. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108(5):1497–1503.
27. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015;90:162–173.
28. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myeofibrosis Reaserch and Treatment. Blood 2009;113:2895–2901.
29. Cerguozzi S. Tefferi A. Blast tranformation and fibrotic progression in polycythemia vera and essential thrombocythemia: literature review of incidence and risk factors. Blood Cancer J 2015;5:11.
30. Kraus M. Zvládání nežádoucích psychiatrických účinků navozených interferonem při léčbě chronické hepatitidy C. Innovations in HCV treatment – sborník odborného sympozia České hepatologické Společnosti ČLS JEP 2004;1:10–11.
31. Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia 2012;26:563–567.
32. Teferi A, Barbui T. Polycythemia vera and essential thrombocythemia. 2015 update on diagnosis, risk stratification and management. Am J Hematol 2015;90:163–173.
33. De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008;93:372–380.
34. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and managements recommendation from European LeukemiaNet, J Clin Oncol 2011;29:761–770.
35. Griesshammer M, Gisslinger H, Mesa R, et al. Curent and future treat-ment otions for polycythemia vera. Ann Hematol 2015;94:901–910.
36. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete molecular responses with low toxicity in polycythemia vera. Blood 2008;112(8):3065–3072.
37. Lengfelder E, Berger U, Hehlmann R. Interferon alfa in the treatment of polycythemia vera. Ann Hematol 2000;79:103–109.
38. Hasselbalch HC, Larsen TS, Riley CH, Jensen MK. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms Status and perspectives. Curr Drug Targets 2011;12:392–419.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2017 Issue 2
Most read in this issue
- Interferon alpha in the treatment of Philadelphia-negative myeloproliferative neoplasms
- Management of major surgery in patients with haemophilia A using continuous infusion vs. bolus injections of FVIII – a pharmacokinetic approach to treatment